Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026
Rhea-AI Summary
Bright Minds Biosciences (NASDAQ:DRUG) will report topline Phase 2 results for BMB-101 on January 6, 2026 at 8:00 AM ET. The company said the announcement covers patients with drug-resistant absence seizures and developmental and epileptic encephalopathy.
A live conference call and webcast will present the data, include a discussion and a Q&A session, and a replay will be posted in the company’s Investors > Events and Presentations section after the event. Participants can submit questions using the webcast "Questions" tab.
Positive
- None.
Negative
- None.
News Market Reaction 23 Alerts
On the day this news was published, DRUG declined 4.13%, reflecting a moderate negative market reaction. Argus tracked a peak move of +63.2% during that session. Argus tracked a trough of -9.6% from its starting point during tracking. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $27M from the company's valuation, bringing the market cap to $623M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
DRUG gained 6.95% while close biotech peers like LRMR (-3.72%), ASMB (-4.15%), IMRX (-2.51%), MBX (-4.71%), and TECX (-0.33%) declined, pointing to a stock-specific move tied to the upcoming topline data.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 25 | Conference appearances | Positive | +1.0% | Highlighted 5-HT2 agonist work at major December 2025 healthcare and epilepsy meetings. |
| Nov 17 | Advisory board expansion | Positive | +0.2% | Added PWS experts to advisory board supporting BMB-101 and BMB-105 development. |
| Nov 06 | Program initiation | Positive | +7.5% | Launched PWS program, NOVA Phase 2a BMB-101 study, and BMB-105 Phase 1 plans. |
| Oct 30 | Conference and options | Positive | +0.5% | Outlined November 2025 conference talks and granted director and officer stock options. |
| Sep 04 | Preclinical results | Positive | +1.6% | Reported BMB-201 outperformed sumatriptan in a validated preclinical headache model. |
Recent pipeline and event-driven announcements have typically produced modest positive price reactions, with a stronger move following the November 2025 PWS program update.
Over the last six months, Bright Minds has advanced multiple CNS programs and increased visibility through conferences and advisory board expansions. Notable events include initiating the PWS program and Phase 2a NOVA study, plus highlighting BMB-201’s preclinical efficacy in vascular headache models. These updates saw generally positive one-day moves up to 7.55%. Today’s announcement of a firm January 6, 2026 topline readout date fits the pattern of clinically focused, data-driven catalysts.
Market Pulse Summary
This announcement sets a firm January 6, 2026 date for Phase 2 topline data from BMB-101 in drug-resistant absence seizures and developmental and epileptic encephalopathies, framing a clear clinical catalyst. Recent history shows steady progress across epilepsy, PWS, and vascular headache programs with generally positive single-day reactions. Investors may focus on seizure-control efficacy, safety outcomes, and how BMB-101 results influence the broader 5-HT–targeted CNS pipeline.
Key Terms
phase 2 medical
developmental and epileptic encephalopathy medical
5-ht receptor agonists medical
AI-generated analysis. Not financial advice.
– Conference Call and Live Webcast at 8AM ET –
NEW YORK, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (Nasdaq: DRUG) (“Bright Minds” or the “Company”), a clinical-stage biotechnology company focused on developing highly selective 5-HT receptor agonists for neurological and psychiatric disorders, today announced that it will host a conference call and live webcast at 8:00AM ET on January 6, 2026, to report topline results for the Phase 2 trial of BMB-101 in patients with drug-resistant Absence Seizures and Developmental and Epileptic Encephalopathy.
Webcast Information
The Bright Minds virtual event will be webcast live and a replay will be available after the event by visiting the “Investors” section of the Company’s website and selecting “Events and Presentations.”
Date and Time: January 6, 2026, 8AM ET
Webcast: https://app.livestorm.co/bright-minds-biosciences/bmb-101-topline-data-announcement
The call will include a discussion of the data followed by a Q&A session. Individuals who wish to ask questions should use the “Questions” tab available during the live webcast.
About Bright Minds Biosciences
Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including Rare Epilepsy, Prader-Willi Syndrome, Depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.
Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.
Contact
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com
Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@investorrelations.com
FAQ
When will Bright Minds (DRUG) release BMB-101 Phase 2 topline results?
What conditions are included in the BMB-101 Phase 2 announcement for DRUG?
How can investors join the Bright Minds (DRUG) webcast for the BMB-101 topline data?
Will Bright Minds (DRUG) make a replay of the BMB-101 presentation available?
Will the BMB-101 webcast include a Q&A session for analysts and investors?
Where is the Bright Minds (DRUG) BMB-101 webcast hosted online?
